Charles R Harrington

List of Publications by Citations

 $\textbf{Source:} \ https://exaly.com/author-pdf/8258527/charles-r-harrington-publications-by-citations.pdf$

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

94 4,003 33 62 g-index

107 4,599 6.8 5.04 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
94	Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996 , 93, 11213-8	11.5	427
93	Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies. <i>Biomolecules</i> , 2016 , 6, 6	5.9	348
92	Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. <i>Lancet, The</i> , 2016 , 388, 2873-2884	40	214
91	Tau-aggregation inhibitor therapy for Alzheimer's disease. <i>Biochemical Pharmacology</i> , 2014 , 88, 529-39	6	183
90	Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease. <i>Journal of Alzheimer Disease</i> , 2015 , 44, 705-20	4.3	168
89	Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease. <i>American Journal of Pathology</i> , 2000 , 157, 623-36	5.8	165
88	Monoaminergic neuropathology in Alzheimer's disease. <i>Progress in Neurobiology</i> , 2017 , 151, 101-138	10.9	137
87	Lack of an association of estrogen receptor alpha gene polymorphisms and transcriptional activity with Alzheimer disease. <i>Archives of Neurology</i> , 2000 , 57, 236-40		133
86	Alzheimer's-disease-like changes in tau protein processing: association with aluminium accumulation in brains of renal dialysis patients. <i>Lancet, The</i> , 1994 , 343, 993-7	40	112
85	Neuropathological findings in the very old. Results from the first 101 brains of a population-based longitudinal study of dementing disorders. <i>Annals of the New York Academy of Sciences</i> , 2000 , 903, 490-	6 ^{6.5}	102
84	Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease. <i>Acta Neuropathologica</i> , 1996 , 91, 633-41	14.3	101
83	Association between Alzheimer's disease and the NOS3 gene. <i>Annals of Neurology</i> , 1999 , 46, 664-7	9.4	94
82	Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial. <i>Journal of Alzheimer Disease</i> , 2018 , 61, 435-457	4.3	91
81	Loss of synaptic but not cytoskeletal proteins in the cerebellum of chronic schizophrenics. <i>Neuroscience Letters</i> , 2002 , 317, 161-5	3.3	76
80	Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015 , 352, 110-8	4.7	75
79	Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine. <i>Psychopharmacology</i> , 2009 , 202, 53-65	4.7	72
78	Measurement of distinct immunochemical presentations of tau protein in Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 5842-6	11.5	68

77	Evolution of a homopurine-homopyrimidine pentanucleotide repeat sequence upstream of the human inducible nitric oxide synthase gene. <i>Gene</i> , 1997 , 204, 165-70	3.8	67
76	Lowry protein assay containing sodium dodecyl sulfate in microtiter plates for protein determinations on fractions from brain tissue. <i>Analytical Biochemistry</i> , 1990 , 186, 285-7	3.1	63
75	Two actin binding proteins, actin depolymerizing factor and cofilin, are associated with Hirano bodies. <i>NeuroReport</i> , 1995 , 6, 1985-8	1.7	61
74	Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2015 , 290, 10862-75	5.4	59
73	Examination of the validity of the hierarchical model of neuropathological staging in normal aging and Alzheimer's disease. <i>Acta Neuropathologica</i> , 1998 , 95, 154-8	14.3	57
7²	Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models. <i>Behavioural Pharmacology</i> , 2015 , 26, 353-68	2.4	53
71	Quantitative analysis of tau protein in paired helical filament preparations: implications for the role of tau protein phosphorylation in PHF assembly in Alzheimer's disease. <i>Neurobiology of Aging</i> , 1995 , 16, 409-17; discussion 418-31	5.6	53
70	Evaluation of polymorphisms in the presenilin-1 gene and the butyrylcholinesterase gene as risk factors in sporadic Alzheimer's disease. <i>European Journal of Human Genetics</i> , 1999 , 7, 659-63	5.3	52
69	Accumulation of C-terminally truncated tau protein associated with vulnerability of the perforant pathway in early stages of neurofibrillary pathology in Alzheimer's disease. <i>Journal of Chemical Neuroanatomy</i> , 2001 , 22, 65-77	3.2	47
68	Alzheimer's Disease-like Paired Helical Filament Assembly from Truncated Tau Protein Is Independent of Disulfide Crosslinking. <i>Journal of Molecular Biology</i> , 2017 , 429, 3650-3665	6.5	40
67	The molecular pathology of Alzheimer's disease. <i>Neuroimaging Clinics of North America</i> , 2012 , 22, 11-22, vii	3	40
66	Examination of phosphorylated tau protein as a PHF-precursor at early stage Alzheimer's disease. <i>Neurobiology of Aging</i> , 1995 , 16, 433-45	5.6	36
65	Immunohistochemical staging of neurofibrillary degeneration in Alzheimer's disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 1994 , 53, 158-64	3.1	34
64	Biosynthesis of wall teichoic acids in Staphylococcus aureus H, Micrococcus varians and Bacillus subtilis W23. Involvement of lipid intermediates containing the disaccharide N-acetylmannosaminyl N-acetylglucosamine. <i>FEBS Journal</i> , 1985 , 153, 639-45		34
63	The role of the Maillard reaction in other pathologies: Alzheimer's disease. <i>Nephrology Dialysis Transplantation</i> , 1996 , 11 Suppl 5, 7-12	4.3	33
62	Thiazin red as a neuropathological tool for the rapid diagnosis of Alzheimer's disease in tissue imprints. <i>Acta Neuropathologica</i> , 2008 , 116, 507-15	14.3	33
61	The relationship between truncation and phosphorylation at the C-terminus of tau protein in the paired helical filaments of Alzheimer's disease. <i>Frontiers in Neuroscience</i> , 2015 , 9, 33	5.1	32
60	The relationship between clinical dementia and neuropathological staging (Braak) in a very elderly community sample. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1996 , 246, 132-6	5.1	31

59	Presenilin-1 intron 8 polymorphism is not associated with autopsy-confirmed late-onset Alzheimer's disease. <i>Neuroscience Letters</i> , 1997 , 222, 68-9	3.3	30
58	Lewy body variant of Alzheimer's disease: selective neocortical loss of t-SNARE proteins and loss of MAP2 and alpha-synuclein in medial temporal lobe. <i>Scientific World Journal, The</i> , 2009 , 9, 1463-75	2.2	28
57	Competitive ELISA for the measurement of tau protein in Alzheimer's disease. <i>Journal of Immunological Methods</i> , 1990 , 134, 261-71	2.5	27
56	Different pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer's disease and frontotemporal lobar degeneration. <i>Cellular and Molecular Life Sciences</i> , 2015 , 72, 2199-222	10.3	26
55	Calcyclin binding protein and Siah-1 interacting protein in Alzheimer's disease pathology: neuronal localization and possible function. <i>Neurobiology of Aging</i> , 2013 , 34, 1380-8	5.6	25
54	The Neurovascular Unit Dysfunction in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	25
53	The CCTTT polymorphism in the NOS2A gene is associated with dementia with Lewy bodies. <i>NeuroReport</i> , 2000 , 11, 297-9	1.7	23
52	Glycation. NeuroReport, 1994 , 5, 859-861	1.7	23
51	Microsatellite polymorphism of the alpha 1-antichymotrypsin gene locus associated with sporadic Alzheimer's disease. <i>Human Genetics</i> , 1997 , 99, 27-31	6.3	22
50	Tau (297-391) forms filaments that structurally mimic the core of paired helical filaments in Alzheimer's disease brain. <i>FEBS Letters</i> , 2020 , 594, 944-950	3.8	22
49	Absence of abnormal hyperphosphorylation of tau in intracellular tangles in Alzheimer's disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 1995 , 54, 657-63	3.1	20
48	Modeling Prion-Like Processing of Tau Protein in Alzheimer's Disease for Pharmaceutical Development. <i>Journal of Alzheimer Disease</i> , 2018 , 62, 1287-1303	4.3	18
47	A Protein Aggregation Inhibitor, Leuco-Methylthioninium Bis(Hydromethanesulfonate), Decreases Esynuclein Inclusions in a Transgenic Mouse Model of Synucleinopathy. <i>Frontiers in Molecular Neuroscience</i> , 2017 , 10, 447	6.1	16
46	Cysteine-Independent Inhibition of Alzheimer's Disease-like Paired Helical Filament Assembly by Leuco-Methylthioninium (LMT). <i>Journal of Molecular Biology</i> , 2018 , 430, 4119-4131	6.5	15
45	Alpha-Synuclein transgenic mice, h-EsynL62, display Esyn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease. <i>Behavioural Brain Research</i> , 2018 , 339, 153-168	3.4	15
44	Alterations in tau protein metabolism during normal aging. <i>Dementia and Geriatric Cognitive Disorders</i> , 1996 , 7, 95-103	2.6	14
43	Senile dementia of Lewy body type and Alzheimer type are biochemically distinct in terms of paired helical filaments and hyperphosphorylated tau protein. <i>Dementia and Geriatric Cognitive Disorders</i> , 1994 , 5, 215-28	2.6	14
42	Elucidating the Neuropathologic Mechanisms of SARS-CoV-2 Infection. <i>Frontiers in Neurology</i> , 2021 , 12, 660087	4.1	14

(1995-2016)

2016 , 6,		·	
Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer's Disease. <i>Journal of Alzheimer Disease</i> , 2019 , 72, 931-946	4.3	13	
Apolipoprotein E genotype in the prediction of cognitive decline and dementia in a prospectively studied elderly population. <i>Dementia and Geriatric Cognitive Disorders</i> , 1996 , 7, 169-74	2.6	12	
Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia. <i>Journal of Alzheimer</i> Disease, 2020 , 75, 501-519	4.3	11	
Presence of the apolipoprotein E type epsilon 4 allele is not associated with neurofibrillary pathology or biochemical changes to tau protein. <i>Dementia and Geriatric Cognitive Disorders</i> , 1997 , 8, 288-95	2.6	11	
Inhibitors of the Maillard Reaction. <i>CNS Drugs</i> , 1996 , 6, 167-177	6.7	8	
Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model. <i>Current Alzheimer Research</i> , 2020 , 17, 285-296	3	7	
PHF-Core Tau as the Potential Initiating Event for Tau Pathology in Alzheimer's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2020 , 14, 247	6.1	7	
Aluminium, tau protein, and Alzheimer's disease. <i>Lancet, The</i> , 1994 , 344, 204-5	40	6	
Insoluble Vascular Amyloid Deposits Trigger Disruption of the Neurovascular Unit in Alzheimer's Disease Brains. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	6	
Cholinergic and inflammatory phenotypes in transgenic tau mouse models of Alzheimer's disease and frontotemporal lobar degeneration. <i>Brain Communications</i> , 2020 , 2, fcaa033	4.5	5	
Characteristics of neuronal lipofuscin in the superior temporal gyrus in Alzheimer's disease do not differ from non-diseased controls: a comparison with disease-related changes in the superior frontal gyrus. <i>Acta Neuropathologica</i> , 2005 , 109, 490-6	14.3	5	
Aluminosilicate particulate and beta-amyloid in vitro interactions: a model of Alzheimer plaque formation. <i>Biochemical Society Transactions</i> , 1998 , 26, S251	5.1	5	
Paired Helical Filament-Forming Region of Tau (297-391) Influences Endogenous Tau Protein and Accumulates in Acidic Compartments in Human Neuronal Cells. <i>Journal of Molecular Biology</i> , 2020 , 432, 4891-4907	6.5	5	
Increased Cholinergic Response in Esynuclein Transgenic Mice (h-EsynL62). <i>ACS Chemical Neuroscience</i> , 2019 , 10, 1915-1922	5.7	5	
Phospho-Tau Protein Expression in the Cell Cycle of SH-SY5Y Neuroblastoma Cells: A Morphological Study. <i>Journal of Alzheimer Disease</i> , 2019 , 71, 631-645	4.3	4	
Characterisation of an epitope specific to the neuron-specific isoform of human enolase recognised by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of beta/A4-protein. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1993 , 1158, 120-8	4	4	
Structure, biochemistry and molecular pathogenesis of paired helical filaments in Alzheimer's disease 1995 , 9-II		4	
	in Mild to Moderate Alzheimer's Disease. <i>Journal of Alzheimera Disease</i> , 2019 , 72, 931-946 Apolipoprotein E genotype in the prediction of cognitive decline and dementia in a prospectively studied elderly population. <i>Dementia and Geriatric Cognitive Disorders</i> , 1996 , 7, 169-74 Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia. <i>Journal of Alzheimera Disease</i> , 2020 , 75, 501-519 Presence of the apolipoprotein E type epsilon 4 allele is not associated with neurofibrillary pathology or biochemical changes to tau protein. <i>Dementia and Geriatric Cognitive Disorders</i> , 1997 , 8, 288-95 Inhibitors of the Maillard Reaction. <i>CNS Drugs</i> , 1996 , 6, 167-177 Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model. <i>Current Alzheimer Research</i> , 2020 , 17, 285-296 PHF-Core Tau as the Potential Initiating Event for Tau Pathology in Alzheimer's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2020 , 14, 247 Aluminium, tau protein, and Alzheimer's disease. <i>Lancet</i> , <i>The</i> , 1994 , 344, 204-5 Insoluble Vascular Amyloid Deposits Trigger Disruption of the Neurovascular Unit in Alzheimer's Disease Brains. <i>International Journal of Molecular Science</i> , 2021 , 22. Cholinergic and inflammatory phenotypes in transgenic tau mouse models of Alzheimer's disease and frontotemporal lobar degeneration. <i>Brain Communications</i> , 2020 , 2, fcaa033 Characteristics of neuronal lipofuscin in the superior temporal gruss in Alzheimer's disease do not differ from non-diseased controls: a comparison with disease-related changes in the superior frontal gruss. <i>Act Neuropathologica</i> , 2005 , 1998, 26, 5251 Paired Helical Filament-Forming Region of Tau (297-391) Influences Endogenous Tau Protein and Accumulates in Acidic Compartments in Human Neuronal Cells. <i>Journal of Molecular Biology</i> , 2020 , 432, 4891-4907 Increased Cholinergic Response in Esynucl	Apolipoprotein E genotype in the prediction of cognitive decline and dementia in a prospectively studied elderly population. <i>Dementia and Geriatric Cognitive Disorders</i> , 1996, 7, 169-74 2.6 Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia. <i>Journal of Alzheimera Disease</i> , 2020, 75, 501-519 Presence of the apolipoprotein E type epsilon 4 allele is not associated with neurofibrillary pathology or biochemical changes to tau protein. <i>Dementia and Geriatric Cognitive Disorders</i> , 1997, 8, 288-95 Inhibitors of the Maillard Reaction. <i>CNS Drugs</i> , 1996, 6, 167-177 Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model. <i>Current Alzheimer Research</i> , 2020, 17, 285-296 PHF-Core Tau as the Potential Initiating Event for Tau Pathology in Alzheimer's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 247 Aluminium, tau protein, and Alzheimer's disease. <i>Lancet</i> , <i>The</i> , 1994, 344, 204-5 Insoluble Vascular Amyloid Deposits Trigger Disruption of the Neurovascular Unit in Alzheimer's Disease Brains. <i>International Journal of Molecular Sciences</i> , 2021, 22, Cholinergic and inflammatory phenotypes in transgenic tau mouse models of Alzheimer's disease and frontotemporal lobar degeneration. <i>Brain Communications</i> , 2020, 2, Fcaa033 Characteristics of neuronal lipofuscin in the superior temporal gyrus in Alzheimer's disease do not differ from non-diseased controls: a comparison with disease-related changes in the superior frontal gyrus. <i>Acta Neuropathologica</i> , 2005, 109, 490-6 Aluminosilicate particulate and beta-amyloid in vitro interactions: a model of Alzheimer plaque formation. <i>Biochemical Society Transactions</i> , 1998, 26, 5251 Paired Helical Filament-Forming Region of Tau (297-391) Influences Endogenous Tau Protein and Accumulates in Acidic Compartments in Human Neuronal Cells. <i>Journal of Molecular Biology</i> , 2020, 432, 4891-49	Apolipoprotein E genotype in the prediction of cognitive decline and dementia in a prospectively studied elderly population. Dementia and Deriatric Cognitive Disorders, 1996, 7, 169-74 26 12 Apolipoprotein E genotype in the prediction of cognitive decline and dementia in a prospectively studied elderly population. Dementia and Deriatric Cognitive Disorders, 1996, 7, 169-74 Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia. Journal of Alzheimera Disease, 2020, 75, 501-519 Presence of the apolipoprotein E type epsilon 4 allele is not associated with neurofibrillary pathology or biochemical changes to tau protein. Dementia and Geriatric Cognitive Disorders, 1997, 8, 288-95 Inhibitors of the Malllard Reaction. CNS Drugs, 1996, 6, 167-177 67 8 Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model. Current Alzheimer Research, 2020, 17, 285-296 30 7 PHF-Core Tau as the Potential Initiating Event for Tau Pathology in Alzheimer's Disease. Frontiers in Cellular Neuroscience, 2020, 14, 247 Aluminium, tau protein, and Alzheimer's disease. Lancet, The, 1994, 344, 204-5 40 6 Insoluble Vascular Amyloid Deposits Trigger Disruption of the Neurovascular Unit in Alzheimer's Disease Brains. International Journal of Molecular Sciences, 2021, 22, Caada33 45 5 Characteristics of neuronal lipofuscin in the superior temporal gyrus in Alzheimer's disease and frontotemporal lobar degeneration. Bioin Communications, 2020, 2, Fcaada33 Characteristics of neuronal lipofuscin in the superior temporal gyrus in Alzheimer's disease do not differ from non-diseased Controls: a comparison with disease-related changes in the superior frontal gyrus. Acta Neuropathologica, 2025, 19, 490-6 Aluminosilicate particulate and beta-amyloid in vitro interactions: a model of Alzheimer plaque formation. Biochemical Society Transactions, 1998, 26, S251 Paired He

23	Assays for the Screening and Characterization of Tau Aggregation Inhibitors. <i>Methods in Molecular Biology</i> , 2017 , 1523, 129-140	1.4	3
22	Analysis of the Relationship Between Metalloprotease-9 and Tau Protein in Alzheimer's Disease. Journal of Alzheimer& Disease, 2020 , 76, 553-569	4.3	3
21	Characterisation of an antibody relevant to the neuropathology of Alzheimer disease. <i>Alzheimer Disease and Associated Disorders</i> , 1995 , 9, 47-51	2.5	3
20	Oxidative Stress Conditions Result in Trapping of PHF-Core Tau (297-391) Intermediates. <i>Cells</i> , 2021 , 10,	7.9	3
19	O4-08-02: Phase 3 Trial of the TAU Aggregation Inhibitor Leuco-Methylthioninium-Bis (Hydromethanesulfonate) (Lmtm) in Mild to Moderate Alzheimer's Disease 2016 , 12, P351-P352		3
18	Stripline resonator and preamplifier for preclinical magnetic resonance imaging at 4.7 T. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2011 , 24, 331-7	2.8	2
17	Chapter 11:Rationale for Tau-Aggregation Inhibitor Therapy in Alzheimer's Disease and Other Tauopathies. <i>RSC Drug Discovery Series</i> , 2010 , 210-232	0.6	2
16	Changes in a CSF antigen associated with dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 1995 , 6, 281-5	2.6	2
15	The impact of genetic and environmental factors on the pathobiology of Alzheimer's disease: a multifactorial disorder?. <i>International Review of Psychiatry</i> , 1995 , 7, 361-383	3.6	2
14	Authors' response to commentaries. <i>Neurobiology of Aging</i> , 1995 , 16, 423-431	5.6	2
13	Presence of axonal paired helical filament-tau in Alzheimer's disease: submicroscopic localization. Journal of Neuroscience Research, 1994 , 38, 664-9	4.4	2
12	Regional Distribution of Paired Helical Filaments and Normal Tau Proteins in Aging and in Alzheimer's Disease with and without Occipital Lobe Involvement. <i>Dementia and Geriatric Cognitive Disorders</i> , 1992 , 3, 61-69	2.6	2
11	Current Progress and Future Directions for Tau-Based Fluid Biomarker Diagnostics in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	2
10	Molecular Processing of Tau Protein in Progressive Supranuclear Palsy: Neuronal and Glial Degeneration. <i>Journal of Alzheimer Disease</i> , 2021 , 79, 1517-1531	4.3	2
9	National Dementia BioBank: A Strategy for the Diagnosis and Study of Neurodegenerative Diseases in M⊠ico. <i>Journal of Alzheimer Disease</i> , 2020 , 76, 853-862	4.3	1
8	Inhibition of Tau Aggregation as a Basis for Treatment and Prevention of Alzheimer⊠ Disease 2016 , 385	-436	1
7	The Aetiology of Alzheimer Disease: Diverse Routes into a Common Tau Pathway 2001 , 97-132		1
6	Molecular determinants of paired helical filament assembly and its therapeutic implications in Alzheimer's disease. <i>International Review of Psychiatry</i> , 1995 , 7, 299-338	3.6	1

LIST OF PUBLICATIONS

5	Differential compartmental processing and phosphorylation of pathogenic human tau and native mouse tau in the line 66 model of frontotemporal dementia. <i>Journal of Biological Chemistry</i> , 2020 , 295, 18508-18523	5.4	0
4	Long-Term Hydromethylthionine Treatment Is Associated with Delayed Clinical Onset and Slowing of Cerebral Atrophy in a Pre-Symptomatic P301S MAPT Mutation Carrier. <i>Journal of Alzheimera Disease</i> , 2021 , 83, 1017-1023	4.3	O
3	Amyloid fibril formation. <i>Nature Biotechnology</i> , 1994 , 12, 848-849	44.5	
2	Degeneration of basal and limbic networks is a core feature of behavioural variant frontotemporal dementia <i>Brain Communications</i> , 2021 , 3, fcab241	4.5	
1	Tau Protein Phosphorylated at Threonine-231 is Expressed Abundantly in the Cerebellum in Prion Encephalopathies. <i>Journal of Alzheimera</i> Disease, 2021 , 81, 769-785	4.3	